PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Tenofovir disoproxil fumarate→

Tenofovir Disoproxil Fumarate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
202138-50-9
PubChem CID
6398764
Molecular formula
C23H34N5O14P
Molecular weight
635.5 g/mol
Drug class
Acyclic nucleotide phosphonate prodrugantiretroviral reverse-transcriptase inhibitor precursor
Mechanism of action
Tenofovir disoproxil is a prodrug that is hydrolysed to tenofovir and subsequently phosphorylated intracellularly to tenofovir diphosphate. Tenofovir diphosphate competitively inhibits HIV reverse transcriptase and HBV DNA polymerase and causes DNA-chain termination. Fumarate is the salt component; the disoproxil moiety is the prodrug.
Indications / reported uses
  • Treatment of HIV-1 infection in combination with other antiretroviral agents
  • Treatment of chronic hepatitis B in adults and adolescents where authorised; use requires current product-specific eligibility, renal assessment and monitoring

Sources: US DailyMed — Tenofovir disoproxil fumarate · EMA — Viread · NIH HIV drug information — Tenofovir disoproxil fumarate

Identification source: PubChem record (CID 6398764). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Tenofovir Disoproxil Fumarate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Tenofovir Disoproxil Fumarate Permitted Daily Exposure (PDE) report (the Tenofovir Disoproxil Fumarate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Tenofovir Disoproxil Fumarate Occupational Exposure Limit (OEL) report (the Tenofovir Disoproxil Fumarate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.